The Limits of Individualism: Potential Societal Harms from the EAP for Convalescent Plasma
This editorial appears in the September issue of the American Journal of Bioethics
by David Magnus, PhD
This issue features a set of articles addressing allocation issues for drugs for COVID-19 that have not been approved by the FDA but are available through either Emergency Use Authorization or Expanded Access Programs (EAP). Webb et al. propose a framework to guide these decisions. Of particular note, the authors point out that a requirement for EAP programs is that they do not interfere with clinical development, including clinical trials, and that the larger the number of participants, the greater the evidence required for an EAP.…
Source: blog.bioethics.net - Category: Medical Ethics Authors: Keisha Ray Tags: Clinical Trials & Studies Ethics Featured Posts Public Health Research Ethics Uncategorized #diaryofaplagueyear COVID-19 policy Source Type: blogs
More News: Blogging | Clinical Trials | COVID-19 | Emergency Medicine | International Medicine & Public Health | Medical Ethics | Study